videopokerjoker|美股异动丨诺和诺德跌超2%，安进减肥新药中期试验获积极数据

Novo Nordisk (LLYvideopokerjoker.US) fell more than 2% to $121.29. on the news frontvideopokerjokerAmgen's mid-term trial of a new weight-loss drug has received positive data, and if the drug is approved, it will compete with Novo Nordisk's Wegovy and Lilly's Zepbound.

Earlier, some media said that Amgen is trying a new weight-loss drug, whose mechanism of action is different from Novo Nordisk and Lilly products, which can prevent patients from gaining weight even if they stop taking the drug.